en · de · es · pt
melanotan-2-notes.peptides3626.com › Data › Origins And Research Status — Background and Details

Origins And Research Status — Background and Details

By Editorial Desk · published 2026-06-03 · last reviewed 2026-07-08 · Data

reconstitution raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-07-08 and is reviewed periodically as new material appears.

Origins and Research Status

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.

Handling, Storage and Analytical Control

Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.

Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideBelongs to the melanocortin agonist family
Key substitutionsNle4 and D-Phe7Improve resistance to enzymatic degradation
Molecular formulaC50H69N15O9Approximately 1024 g/mol
Regulatory statusNot approved as a medicineDistributed as a research chemical
Common synonymsMelanotan II, MT-II, MT-2Spelling varies across sources

Peptide Identity and Structural Background

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Related pages on this site

Quality Control and Analytical Practice

Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.

Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.

Identity and Chemical Background

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Handling, Storage, and Analytical Verification

Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.

Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.

Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.

Supporting material

== Early life == Brian Rafat Awadis was born on November 19, 1996 in San Diego, California, to immigrant Chaldo-Assyrian parents from Tel Keppe, Iraq. His father owns two stores. He graduated from Mira Mesa Senior High School and attended San Diego Miramar College before dropping out during his freshman year to pursue his YouTube career full-time. He can speak the Suret language, although not fluently.

=== Inquiry === In 2010, an independent inquiry into Norris's murders was held. The inquiry recommended the introduction of 'student practice passports', which would report on the personality and integrity of students while they trained as medical professionals at university. It was felt that this may have flagged up Norris as an issue earlier had they been in use at the time of his studying, since he had knowingly acted aggressively during placements, had a poor absence record and had clashed with tutors on numerous occasions. These 'passports', it was argued, would allow universities to evaluate at the end of a student's course whether the individual was fit to join the medical register. The inquiry found that the University of Dundee had not identified Norris's difficulties in its reference to employers, and the inquiry concluded that organisational, systems and cultural factors provided an opportunity for Norris to murder the four women in 2002. Nurse managers had already been urged after Norris's conviction in 2008 to take greater care when recruiting staff, and NHS employers had introduced new guidance on pre-employment checks.

=== Degradation === In mammals, norepinephrine is rapidly degraded to various metabolites. The initial step in the breakdown can be catalyzed by either of the enzymes monoamine oxidase (mainly monoamine oxidase A) or COMT. From there, the breakdown can proceed by a variety of pathways. The principal end products are either Vanillylmandelic acid or a conjugated form of MHPG, both of which are thought to be biologically inactive and are excreted in the urine.

Sources: en.wikipedia.org

Notes from published material

==== Mechanical exfoliation ==== Geim and Novoselov initially used adhesive tape to pull graphene sheets away from graphite. Achieving single layers typically requires multiple exfoliation steps. After exfoliation, the flakes are deposited on a silicon wafer. Crystallites larger than 1 mm and visible to the naked eye can be obtained. As of 2014, exfoliation produced graphene with the lowest number of defects and highest electron mobility. One specific exfoliation technique involved using a sharp single-crystal diamond wedge to penetrate the graphite source and precisely cleave individual layers. That same year, researchers also developed liquid-phase methods, creating defect-free, unoxidized graphene-containing liquids from graphite using mixers that generate extremely high local shear rates greater than 10×104. A 2014 study published in Nature Materials demonstrated that scalable production of defect-free graphene is possible through shear exfoliation using a high-shear mixer. This technique can produce large quantities of few-layer graphene in solution while preserving structural integrity. As turbulence is not necessary for mechanical exfoliation, resonant acoustic mixing or low-speed ball milling can also be effective in the production of high-yield and water-soluble graphene.

== Sources == Furlow, John J. (1997). "Betula". In Flora of North America Editorial Committee (ed.). Flora of North America North of Mexico (FNA). Vol. 3. New York and Oxford: Oxford University Press – via eFloras.org, Missouri Botanical Garden, St. Louis, Missouri and Harvard University Herbaria, Cambridge, Massachusetts. Li, Pei-chun; Skvortsov, Alexei K. "Betula". Flora of China. Vol. 4 – via eFloras.org, Missouri Botanical Garden, St. Louis, Missouri and Harvard University Herbaria, Cambridge, Massachusetts. Grimshaw, John (2009). New Trees, Recent introductions to cultivation. Kew Publishing, RBG Kew. pp. 163–174. Chisholm, Hugh, ed. (1911). "Birch" . Encyclopædia Britannica. Vol. 3 (11th ed.). Cambridge University Press. Jonczak, Jerzy; Jankiewicz, Urszula; Kondras, Marek; Kruczkowska, Bogusława; Oktaba, Lidia; Oktaba, Jarosław; Olejniczak, Izabella; Pawłowicz, Edyta; Polláková, Nora; Raab, Thomas; Regulska, Edyta; Słowińska, Sandra; Sut-Lohmann, Magdalena (December 2020). "The influence of birch trees (Betula spp.) on soil environment – A review". Forest Ecology and Management. 477 118486. Bibcode:2020ForEM.47718486J. doi:10.1016/j.foreco.2020.118486.

A third family of alcohol dehydrogenases, unrelated to the above two, are iron-containing ones. They occur in bacteria and fungi. In comparison to enzymes of the above families, these enzymes are oxygen-sensitive. Members of the iron-containing alcohol dehydrogenase family include:

Sources: en.wikipedia.org

Further detail

PDB Molecule of the Month Serpin Merops protease inhibitor claudication (Family I4) Archived 8 December 2016 at the Wayback Machine Serpins at the U.S. National Library of Medicine Medical Subject Headings (MeSH) James Whisstock laboratory at Monash University Jim Huntington laboratory Archived 30 October 2016 at the Wayback Machine at University of Cambridge Frank Church laboratory at University of North Carolina at Chapel Hill Paul Declerck laboratory at Katholieke Universiteit Leuven Tom Roberts laboratory at University of Sydney Robert Fluhr laboratory Archived 19 October 2014 at the Wayback Machine at Weizmann Institute of Science Peter Gettins laboratory at University of Illinois at Chicago Overview of all the structural information available in the PDB for UniProt: P01009 (Human Alpha-1-antitrypsin) at the PDBe-KB.

== History == 3,4-DMA was first described in the scientific literature by Gordon Alles by 1932. Its effects in humans were first described by Mahlon David Fairchild by 1963. Subsequently, the drug was described in greater detail by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.

== Mechanism == Many cells have other mechanisms to pump a molecule inside or outside the cell against the concentration gradient, but these processes are active ones, meaning that they require enzymes and consume cellular energy. In contrast, ion trapping does not require any enzyme or energy. It is similar to osmosis in that they both involve the semipermeable nature of the cell membrane. Cells have a more acidic pH inside the cell than outside (gastric mucosal cells being an exception). Therefore, basic drugs (like bupivacaine, pyrimethamine) are more charged inside the cell than outside. The cell membrane is permeable to non-ionized (fat-soluble) molecules; ionized (water-soluble) molecules cannot cross it easily. Once a non-charged molecule of a basic chemical crosses the cell membrane to enter the cell, it becomes charged due to gaining a hydrogen ion because of the lower pH inside the cell, and thus becomes unable to cross back. Because transmembrane equilibrium must be maintained, another unionized molecule must diffuse into the cell to repeat the process. Thus its concentration inside the cell increases many times that of the outside. The non-charged molecules of the drug remain in equal concentration on either side of the cell membrane. The charge of a molecule depends upon the pH of its solution. In an acidic medium, basic drugs are more charged and acidic drugs are less charged. The converse is true in a basic medium. For example, Naproxen is a non-steroidal anti-inflammatory drug that is a weak acid (its pKa value is 5.0). The gastric juice has a pH of 2.0.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan II?

It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.

Is melanotan II an approved medicine?

No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.

What do published reports describe?

Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.

How is peptide purity usually reported?

Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.

Network